International Psoriasis Council

Advancing Knowledge. Improving Care.

PsoProtect Registry Data Update

psoprotect_update_615

PsoProtect, a global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis, has updated their preliminary data and now includes the first 1,652 cases. Below is a summary of the data collected or view the full report on the PsoProtect website.

Average age: 48 years
Phenotype of psoriasis: 1,605 plaque psoriasis, 47 pustular psoriasis
Average BMI: 27.7 kg/m2
Average number of days of symptoms from COVID-19: 10 days

Cases reported by country of assessment (≥20 cases):

PsoProtect 6-15-22_country

Severity of psoriasis at time of onset of COVID-19 (PGA):

PsoProtect 6-15-22_severity

Hospitalization required due to COVID-19:

PsoProtect 6-15-22_hospital

In addition to demographics, PsoProtect collects the following types of de-identified data:

  • Psoriasis disease characteristics, comorbidities and systemic treatment for psoriasis at onset of COVID-19
  • COVID-19 characteristics and disease course
  • COVID-19 outcome

We encourage clinicians to continue reporting cases of COVID-19 (suspected or confirmed) in psoriasis via the simple online PsoProtect case report form.

*Data are preliminary and include a limited number of cases and should not be used to inform clinical decision making

[searchwp_search_form engine=blog_search target="/news" var=_blog_search]

Categories

Recent Posts

Six people stand side by side in business attire, smiling at the camera. Behind them, a banner reads IPC International Council 2025 Think Tank Puerto Rico, focused on Psoriasis in Latin America, with colorful designs and sunlight filtering through curtains.

Next Generation of Leaders: 2025 IPC Fellows Transition to Jr. Councilors

VIEW
A large group attends a conference session, with several panelists seated at a table onstage. One attendee stands to ask a question. The IPC (International Psoriasis Council) logo and AAD 2026 appear in the corner.

Highlights from the 2026 American Academy of Dermatology (AAD) Annual Meeting: Diagnostic Complexity, Therapeutic Advances, and Emerging Research

VIEW
A man in a suit smiles at the camera next to text that reads, World Psoriasis Experts Give Their Take on Current, Hot, or Controversial Topics like Biologics in Psoriasis Management. EXPERT COMMENTARY.

First-Line Biologics in Psoriasis: Evidence from the BADBIR Cohort Study

VIEW

Also Read

A banner showing “IPC-GRAPPA Joint Consensus Initiative: Difficult-to-Treat / Treatment-Refractory Psoriasis” with IPC and GRAPPA logos, a world map in the background, and recognition of an IPC Board Member.
difficult-to-treat psoriasis

IPC and GRAPPA Launch Joint Consensus Initiative on Difficult-to-Treat Psoriasis

The International Psoriasis Council (IPC) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) have launched a global consensus initiative to define difficult-to-treat and treatment-refractory psoriasis, with the goal of improving clinical care, research consistency, and treatment decision-making worldwide.

Read More
Tuesday, March 24, 2026

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.
Subscribe

What's New

First-Line Biologics in Psoriasis: Evidence from the BADBIR Cohort Study

In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.

Read More »
Monday, April 27, 2026

Recent Advances in Psoriasis: A Year in Review

In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.

WATCH NOW

Monday, April 6, 2026